IL2 and infection: This selective expansion of immune regulatory cells showed promise in studies conducted by Zhao et al. and He et al., which was premised on the rationale behind the expected lower incidence of adverse effects among these individuals. However, this study was conducted over a course of only five days of observation; hence, it was not enough to estimate the direct effect of low-dose IL2 on the treatment of infection, and whether low-dose IL2 therapy could reduce infection rates needed further studies [17].